Cost effectiveness of lowering cholesterol. Full treatment of the costs and benefits is needed.
作者信息
Wierzbicki A S, Reynolds T M
出版信息
BMJ. 1996 Nov 2;313(7065):1143; author reply 1144. doi: 10.1136/bmj.313.7065.1143.
Abstract
摘要
相似文献
1
Cost effectiveness of lowering cholesterol. Full treatment of the costs and benefits is needed.降低胆固醇的成本效益。需要全面考量成本与效益。
BMJ. 1996 Nov 2;313(7065):1143; author reply 1144. doi: 10.1136/bmj.313.7065.1143.
2
Cost effectiveness of lowering cholesterol. Study greatly underestimates the cost effectiveness of statin treatment.降低胆固醇的成本效益。该研究极大地低估了他汀类药物治疗的成本效益。
BMJ. 1996 Nov 2;313(7065):1142; author reply 1144. doi: 10.1136/bmj.313.7065.1142a.
3
Cost effectiveness of lowering cholesterol. Study did not take account of confounders.降低胆固醇的成本效益。该研究未考虑混杂因素。
BMJ. 1996 Nov 2;313(7065):1142-3; author reply 1144. doi: 10.1136/bmj.313.7065.1142b.
4
Cost effectiveness of lowering cholesterol. Cost consequence analysis may be more useful to decision makers.降低胆固醇的成本效益。成本后果分析可能对决策者更有用。
BMJ. 1996 Nov 2;313(7065):1142; author reply 1144. doi: 10.1136/bmj.313.7065.1142.
5
Cost effectiveness of lowering cholesterol. Statin treatment should be started early.降低胆固醇的成本效益。他汀类药物治疗应尽早开始。
BMJ. 1996 Nov 2;313(7065):1143; author reply 1144. doi: 10.1136/bmj.313.7065.1143a.
6
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.他汀类药物降低已有或无冠心病患者胆固醇浓度的成本效益：应用于卫生当局人群的生命表法
BMJ. 1996 Jun 8;312(7044):1443-8. doi: 10.1136/bmj.312.7044.1443.
7
[Limitations of interventions against hypercholesterolemia].
Aten Primaria. 1996 Mar 15;17(4):305-6.
8
Cost effectiveness of lowering cholesterol. Costs in general practice.降低胆固醇的成本效益。全科医疗中的成本。
BMJ. 1996 Nov 2;313(7065):1143-4. doi: 10.1136/bmj.313.7065.1143b.
9
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.载脂蛋白 B 代谢途径抑制剂治疗杂合子型家族性高胆固醇血症或动脉粥样硬化性心血管疾病患者的成本效果分析。
JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.
10
Cost implications of lipid-lowering treatments.降脂治疗的成本影响。
Pharmacoeconomics. 1994 Oct;6(4):310-23. doi: 10.2165/00019053-199406040-00002.
本文引用的文献
1
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S).降低胆固醇的成本效益。斯堪的纳维亚辛伐他汀生存研究（4S）的结果。
Eur Heart J. 1996 Jul;17(7):1001-7. doi: 10.1093/oxfordjournals.eurheartj.a014994.
2
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.他汀类药物降低已有或无冠心病患者胆固醇浓度的成本效益：应用于卫生当局人群的生命表法
BMJ. 1996 Jun 8;312(7044):1443-8. doi: 10.1136/bmj.312.7044.1443.
3
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.
Circulation. 1996 May 15;93(10):1796-802. doi: 10.1161/01.cir.93.10.1796.
4
Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease.用于预防冠心病的胆固醇降低的谢菲尔德风险与治疗表。
Lancet. 1996 Feb 17;347(8999):468; author reply 468-9.
5
Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease.
Lancet. 1996 Feb 17;347(8999):466-7; author reply 468-9.
6
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.普伐他汀预防高胆固醇血症男性冠心病。苏格兰西部冠心病预防研究组。
N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001.
7
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease.用于冠心病一级预防的胆固醇降低的谢菲尔德风险与治疗表。
Lancet. 1995 Dec 2;346(8988):1467-71. doi: 10.1016/s0140-6736(95)92477-9.
Zotero 插件